Table 2 Comparison of imaging features of HCCs and non-malignant nodules, LR-3 and LR-4
LI-RADS features | HCCs(n = 311) | Non-HCC nodules(n = 162) | P value | LR-3 lesions(n = 153) | LR-4 lesions(n = 129) | LR-5 lesions(n = 191) | P value** |
|---|---|---|---|---|---|---|---|
Major HCC features | |||||||
Diameter: <10 mm | 4.2(13/311) | 25.3(41/162) | 0.000 | 31.4(48/153) | 3.9(5/129) | 0.5(1/191) | 0.000 |
Diameter: 10–19 mm | 25.1(78/311) | 42.0(68/162) | 0.000 | 60.8(93/153) | 17.8(23/129) | 15.7(30/191) | 0.000 |
Diameter:≥20 mm | 70.7(220/311) | 32.7(53/162) | 0.000 | 7.8(12/153) | 78.3(101/129) | 83.8(160/191) | 0.000 |
Non-rim APHE | 79.7(248/311) | 55.6(90/162) | 0.000 | 52.3(80/153 | 53.5(69/129) | 99.0(189/191) | 0.000 |
Non-peripheral washout | 59.8(186/311) | 10.5(17/162) | 0.000 | 7.2(11/153) | 41.1(53/129) | 72.8(139/191) | 0.000 |
Enhancing capsule | 56.9(177/311) | 11.1(18/162) | 0.000 | 1.3(2/153) | 41.1(53/129) | 73.3(140/191) | 0.000 |
Ancillary features Favoring malignancy in general | |||||||
Mild-moderate T2 hyperintensity | 81.0(252/311) | 50.0(81/162) | 0.000 | 52.9(81/153) | 72.9(94/129) | 82.7(158/191) | 0.000 |
Fat sparing in solid mass | 9.0(28/311) | 9.9(16/162) | 0.742 | 7.8(12/153) | 12.4(16/129) | 8.4(16/191) | 0.359;0.377;0.931 |
Iron sparing in solid mass | 4.8(15/311) | 0.6(1/162) | 0.015 | 1.3(2/153) | 4.7(6/129) | 4.2(8/191) | 0.220;0.170;0.158 |
Corona enhancement | 10.3(32/311) | 9.9(16/162) | 1.000 | 5.2(8/153) | 15.5(20/129) | 10.5(20/191) | 0.017;0.015;0.145 |
TP hypointensity | 25.4(79/311) | 13.0(21/162) | 0.002 | 16.3(25/153) | 25.6(33/129) | 22.0(42/191) | 0.155;0.151;0.235 |
HBP hypointensity | 25.7(80/311) | 14.8(24/162) | 0.007 | 19.6(30/153) | 25.6(33/129) | 21.5(41/191) | 0.471;0.476;0.730 |
Restricted diffusion | 87.1(271/311) | 58.6(95/162) | 0.000 | 60.1(92/153) | 82.9(107/129) | 88.0(168/191) | 0.000 |
Ancillary features Favoring HCC in particular | |||||||
Nodule-in-nodule appearance | 1.0(3/311) | 0(0/162) | 0.554 | 0(0/153) | 0.8(1/129) | 1.0(2/191) | 0.464;0.299;0.231 |
Mosaic appearance | 11.6(36/311) | 0(0/162) | 0.000 | 0(0/153) | 10.1(13/129) | 12.0(23/191) | 0.000 |
Blood product in mass | 17.7(55/311) | 0(0/162) | 0.000 | 1.3(2/153) | 16.3(21/129) | 16.8(32/191) | 0.000 |
Fat in mass | 30.5(95/311) | 11.1(18/162) | 0.000 | 15.0(23/153) | 20.2(26/129) | 33.5(64/191) | 0.000 |
Non-enhancing capsule | 13.5(42/311) | 3.7(6/162) | 0.001 | 3.9(6/153) | 10.1(13/129) | 15.2(29/191) | 0.003;0.002;0.001 |
Ancillary features Favoring benignity | |||||||
Parallel blood pool | 1.0(3/311) | 9.3(15/162) | 0.000 | 7.2(11/153) | 5.4(7/129) | 0(0/191) | 0.001 |
Undistorted vessels | 3.5(11/311) | 0.6(1/162) | 0.066 | 0.7(1/153) | 3.9(5/129) | 3.1(6/191) | 0.182;0.124;0.165 |
Iron in mass more than liver | 0(0/311) | 0(0/162) | NA | 0(0/153) | 0(0/129) | 0(0/191) | NA |
Marked T2 hyperintensity | 1.0(3/311) | 21.6(35/162) | 0.000 | 16.3(25/153) | 8.5(11/129) | 1.0(2/191) | 0.000 |
HBP isointensity | 1.6(5/311) | 16.7(27/162) | 0.000 | 15.0(23/153) | 5.4(7/129) | 1.0(2/191) | 0.000 |